Skip to content

Raloxifene

Raloxifene (Evista) appears in one listed tablet product, Evista.

Evista

Postmenopausal Osteoporosis Prevention

60mg

Developed to mitigate postmenopausal bone density loss to support skeletal matrix strength and target breast tissue safety.

From$0.80/ tabletView

Which conditions are associated with Raloxifene?

One listed use is Postmenopausal Osteoporosis Prevention. Another treatment context is Breast Cancer Risk Reduction. Related medicines appear within Oncology Support. The wider Bone Health section groups products with a related treatment focus.

Important safety information for Raloxifene

Information about Raloxifene on this page is an educational overview, not medical advice. Products can differ in formulation, strength, and directions, and this content does not authorise clinical application or unsupervised use. Review the labelling for each product and speak with a healthcare professional whenever clinical judgement is needed. Product-specific contraindications, interactions, and reactions should be checked in the product labelling and verified clinical sources.